Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed. In one version of the method, the stilbene derivative is a compound of formula (X):
1. A method for detecting or ruling out a meningioma in a patient, the method comprising:
(a) administering to a patient a detectable amount of a compound of formula (VI):
wherein the compound is targeted to any meningiomas in the patient,
wherein R 4 is selected from the group consisting of H, OH, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, and substituted or unsubstituted carboxylate,
wherein n is an integer from 0 to 10,
wherein X is selected from the group consisting of 3 H, 11 C, 13 C, 14 C, 13 N, 15 O, 75 Br, 76 Br, 18 F, 19 F, 68 Ga, 82 Rb, 111 In, 123 I, 125 I, 131 I, 201 Tl, and 99m Tc; and
(b) acquiring an image of the patient;
(c) evaluating the image to detect meningiomas that do not contain amyloid; and
(d) detecting the meningioma in the patient based on detected meningiomas that do not contain amyloid.
2. The method of claim 1 wherein:
R 4 is methylamino or dimethylamino.
3. The method of claim 1 wherein:
R 4 is methylamino, and
X is 18 F.
4. The method of claim 3 wherein:
n is 3.
5. The method of claim 1 wherein step (b) comprises acquiring the image using an imaging method selected from positron emission tomography imaging, single photon emission computed tomography imaging, positron emission tomography with computed tomography imaging, positron emission tomography with magnetic resonance imaging, single photon emission computed tomography with computed tomography imaging, or any combination thereof.
6. The method of claim 1 wherein step (b) comprises acquiring the image using positron emission tomography imaging.
7. The method of claim 1 wherein step (b) comprises acquiring the image using single photon emission computed tomography imaging.
8. The method of claim 1 wherein step (b) comprises acquiring the image using positron emission tomography with computed tomography imaging.
9. The method of claim 1 wherein step (b) comprises acquiring the image using positron emission tomography with magnetic resonance imaging.
10. The method of claim 1 wherein step (b) comprises acquiring the image using single photon emission computed tomography with computed tomography imaging.
11. The method of claim 1 wherein the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than normal adjacent tissues imaged.
12. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any other intracranial tumors imaged.
13. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any metastases, pituitary macroadenomas, schwannomas, or ependymomas imaged.
14. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than any metastases imaged.
15. A method for detecting or ruling out a meningioma in a patient, the method comprising:
(a) administering to a patient a detectable amount of a compound of formula (VIII):
wherein the compound is targeted to any meningiomas in the patient,
wherein R 4 is selected from the group consisting of H, OH, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, and substituted or unsubstituted carboxylate,
wherein n is an integer from 0 to 10,
wherein X is selected from the group consisting of 3 H, 11 C, 13 C, 14 C, 13 N, 15 O, 75 Br, 76 Br, 18 F, 19 F, 68 Ga, 82 Rb, 111 In, 123 I, 125 I, 131 I, 201 Tl, and 99m Tc; and
(b) acquiring an image of the patient;
(c) evaluating the image to detect meningiomas that do not contain amyloid; and
(d) detecting the meningioma in the patient based on detected meningiomas that do not contain amyloid.
16. The method of claim 15 wherein:
R 4 is methylamino or dimethylamino.
17. The method of claim 15 wherein:
R 4 is methylamino, and
X is 18 F.
18. A method for detecting or ruling out a meningioma in a patient, the method comprising:
(a) administering to a patient a detectable amount of a compound of formula (IX):
wherein the compound is targeted to any meningiomas in the patient,
wherein R 4 is selected from the group consisting of H, OH, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, and substituted or unsubstituted carboxylate,
wherein n is an integer from 0 to 10,
wherein X is selected from the group consisting of 3 H, 11 C, 13 C, 14 C, 13 N, 15 O, 75 Br, 76 Br, 18 F, 19 F, 68 Ga, 82 Rb, 111 In, 123 I, 125 I, 131 I, 201 Tl, and 99m Tc; and
(b) acquiring an image of the patient;
(c) evaluating the image to detect meningiomas that do not contain amyloid; and
(d) detecting the meningioma in the patient based on detected meningiomas that do not contain amyloid.
19. The method of claim 18 wherein:
R 4 is methylamino or dimethylamino.
20. The method of claim 18 wherein:
R 4 is methylamino, and
X is 18 F.